NCT03160430View on ClinicalTrials.gov

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

November 22, 2026

Study Completion Date

November 22, 2026

Conditions
Kidney Failure, Chronic
Interventions
DRUG

apabetalone

RVX000222 oral (apabetalone), 100 mg capsule

DRUG

Placebos

matching placebo capsule

All Listed Sponsors
lead

Resverlogix Corp

INDUSTRY